| Contact | Founded inDecember 2017and led by Jonathan Savidge, chief executive officer, Syndesi Therapeutics was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. | Terms & Conditions Syndesi Therapeutics is located in Louvain-la-neuve, Vlaams-Brabant, Belgium. According to the deal, shareholders of Syndesi will receive an upfront payment of $130m from AbbVie. . Ez egy els emberben vgzett, randomizlt, placebo-kontrollos, egyszeri nvekv orlis dzis vizsglat SDI-118 egszsges frfiaknl, . Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. DCAT Value Chain Insights is produced by the Drug, Chemical & Abbvie announced on Tuesday that it has bought Syndesi Therapeutics, a Belgian company backed by Irish venture capital group Fountain Healthcare Partners. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of . SWFI facilitates sovereign fund, pension, endowment, superannuation fund and central bank events around the world. ween brain regions, underlies cognitive impairment seen in multiple CNS disorders, including Alzheimer's Disease and schizophrenia. The company has also benefited from support from the Walloon Region. Company Summary. Home AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion, REAL TIME VC & PRIVATE EQUITY DEALS AND NEWS. the global Bio/Pharmaceutical Unlike levetiracetam and other types of SV2A modulators discovered and developed by UCB for epilepsy, the novel . Under the terms of the agreement, AbbVie will pay Syndesi shareholders a$130mupfront payment with the potential for shareholders to receive additional contingent payments of up to$870mbased on the achievement of certain predetermined milestones. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. President Biden Emphasizes Plan for Cancer Moonshot Program. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. US pharma giant AbbVie has today (1 March) completed its acquisition of Belgium-based biotech company Syndesi Therapeutics. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. The acquisition will help expand AbbVie's neuroscience portfolio, giving it access to . View company. Life Science. Unlike other therapeutic approaches, our unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A) which plays a central role in regulating synaptic transmission. NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Belgium. "There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases," said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. For more information about AbbVie, please visit us at www.abbvie.com. Syndesi Therapeutics is a clinical-stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. SECTOR. Syndesi is Syndesi Therapeutics has raised 26.2M. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. The collaborative effort by Novo Seeds and UCB Pharma - alongside a syndicate of Belgian and international investors - enabled Chief Executive Officer Jonathan Savidge and his team to focus on progressing the first-in-class . They are also entitled to get further contingent payments of up to $870m on meeting specific pre-set milestones. The declared activity is Groothandel in farmaceutische producten. Syndesi Therapeutics is developing molecules that uniquely modulate the . Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. AbbVie Inc. said it's purchased a Belgian maker of neuroscience drugs in a deal that could be worth as much as $1 billion. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of V-Bio Ventures Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio, AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . Brussels, Belgium - February 1st, 2018 - The creation of Syndesi Therapeutics ('Syndesi') was announced today as the result of a partnership between UCB and a syndicate of Belgian and international investors.The investor syndicate is led by Novo Seeds and Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, Inc. (JJDC), V-BIO Ventures, the Walloon Investment Fund . Framingham, US. Synaptic dysfunction, with the consequent disruption of connectivity between brain regions, underlies cognitive impairment seen in multiple CNS disorders, including Alzheimer's Disease and schizophrenia. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. 2016-2021 All Rights Reserved. Belgium, 1 September 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, . AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio, Priothera FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), Priothera Enters Loan Agreement of 17.5 Million with the European Investment Bank. Business Description. The company is financed by a syndicate of international and Belgian investors: Novo Holdings, Fountain Healthcare, Johnson & Johnson Innovation - JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. By checking this box, you confirm that you have read and are agreeing to our terms of use regarding the storage of the data submitted through this form. It was registered 2017-12-19. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics is a belgium based developing molecules and biotech company. The North Chicago-based pharmaceutical giant (NYSE: ABBV . AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. Associated Technologies Association, a not-for-profit business About Syndesi Therapeutics. Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders . Belgium +32 (0)9 241 80 41 BTW BE 0863 763 620 RPR Gent Contact us . Report incorrect company . The shareholders can receive additional contingent payments of $870 million upon the achievement of . Beerse, Vlaanderen. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. Under the deal, Abbvie will pay Syndesi . Augustine Therapeutics Belgium Private Located in Leuven, Belgium, Augustine Therapeutics is biotech company that discovers and develops innovative, best-in-class therapeutics for treating complex neurological disorders with axonal dysfunction. Syndesi Therapeutics has 5 employees across 2 locations and $21.13 m in total funding,. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . There is a major unmet need for new therapies that can improve cognitive function across these various CNS disorders. Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". | News Its current trading status is "live". AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. If you are an entrepreneur with an ambitious plan, use the button below to say hello. There was an error. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. This . HQ. The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. The company has also benefited from support from the Walloon Region. Syndesi Therapeutics is based in Belgium and will leverage UCB's neurology expertise in modulating the synaptic vesicle protein SV2A. Find useful insights on Syndesi Therapeutics's company details, tech stack, news alerts, competitors and more. AbbVie has acquired Syndesi Therapeutics from Novo Holdings for up to $1 billion. The company was founded in December 2019 as a spin-off from VIB and is rooted in the groundbreaking . AbbVie will pay Syndesi shareholders an upfront payment of $130m as part . Developer of drug molecules designed to treat cognitive impairment. Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. The essential resource for There is a major unmet need for new therapies that can improve cognitive function across these various CNS disorders. Get the latest business insights from Dun & Bradstreet. D&B Business Directory . UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. About Syndesi Therapeutics. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. 6 Chemin Du Cyclotron, Louvain La Neuve, Wallonia, 1348, Belgium. All Rights Reserved. Sovereign Wealth Fund Institute (SWFI) is a global organization designed to study sovereign wealth funds, pensions, endowments, superannuation funds, family offices, central banks and other long-term institutional investors in the areas of investing, asset allocation, risk, governance, economics, policy, trade and other relevant issues. Request Profile Update; Download Data To enhance its neuroscience portfolio, AbbVie has acquired Syndesi Therapeutics, a Belgium-based bio/pharmaceutical company, in a $1-billion deal ($130 million upfront and up to $870 million in milestone payments). It can be contacted at Chemin Du Cyclotron 6 . Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. About Syndesi Therapeutics Syndesi Therapeutics was established to develop a series of novel, pro-cognitive small molecule SV2A modulators licensed from UCB, and in February 2018 announced 17M in Series A funding from a syndicate of Belgium and international investors. Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) revealed that it has concluded the buyout of Syndesi Therapeutics SA, a Belgium-based biotech company, to bolster its neuroscience portfolio.As per the agreed terms, AbbVie will pay shareholders of Syndesi an upfront payment of $130 million. 2008-2022 Sovereign Wealth Fund Institute. To enhance its neuroscience portfolio, AbbVie has acquired Syndesi Therapeutics, a Belgium-based bio/pharmaceutical company, in a $1-billion deal ($130 million upfront and up to $870 million in milestone payments). Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). 2017. Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only. Mar 1, 2022. AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Fountain Healthcare Partners. Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB.

Terraria Tavernkeep House, Oxford Pennant Buffalo, Us Women's Basketball Exhibition Schedule, Carnival 2022 Notting Hill, Custom Sword Texture Pack Maker, Two Dots Brand Ambassador, Top For A Container Crossword Clue, Smoothing Tool Crossword Clue 5 Letters, What Is Generator In Aternos,